Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 24, 2016
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALAaron I Vinik, Edward M Wolin, Nilani Liyanage, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 4, 2009
Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotideMartina L Zalom, Alan D Waxman, Run Yu, et al.Chest|November 29, 2012
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 studyNicola Fazio, Dan Granberg, Ashley Grossman, et al.Pancreas|April 13, 2011
Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1Anna Milanesi, Run Yu, Stephen A Geller, et al.Pancreas|March 23, 2017
Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United StatesEdward M Wolin, John Leyden, Grace Goldstein, et al.Journal of Gastrointestinal Cancer|September 14, 2016
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine TumorsEdward M Wolin, Amandine Manon, Christophe Chassaing, et al.The Oncologist|October 18, 2017
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label StudyGeorge A Fisher, Edward M Wolin, Nilani Liyanage, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 17, 2018
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDYGeorge A Fisher, Edward M Wolin, Nilani Liyanage, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 10, 2017
Multifocality in Small Bowel Neuroendocrine TumorsAlexandra Gangi, Emily Siegel, Galinos Barmparas, et al.Investigational New Drugs|November 13, 2014
Pharmacokinetic study of aldoxorubicin in patients with solid tumorsMonica M Mita, Ronald B Natale, Edward M Wolin, et al.Pageof 5